NO320170B1 - Fremgangsmate for a male konsentrasjonen og/eller det relative innholdet av et spesifikt antistoff i en prove og anvendelser derav. - Google Patents
Fremgangsmate for a male konsentrasjonen og/eller det relative innholdet av et spesifikt antistoff i en prove og anvendelser derav. Download PDFInfo
- Publication number
- NO320170B1 NO320170B1 NO19951875A NO951875A NO320170B1 NO 320170 B1 NO320170 B1 NO 320170B1 NO 19951875 A NO19951875 A NO 19951875A NO 951875 A NO951875 A NO 951875A NO 320170 B1 NO320170 B1 NO 320170B1
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- bound
- solid phase
- sample
- ige
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 230000008569 process Effects 0.000 title description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 52
- 239000002245 particle Substances 0.000 claims abstract description 47
- 239000007790 solid phase Substances 0.000 claims abstract description 47
- 230000005298 paramagnetic effect Effects 0.000 claims abstract description 30
- 229960002685 biotin Drugs 0.000 claims abstract description 25
- 235000020958 biotin Nutrition 0.000 claims abstract description 25
- 239000011616 biotin Substances 0.000 claims abstract description 25
- 239000003446 ligand Substances 0.000 claims abstract description 25
- 108010090804 Streptavidin Proteins 0.000 claims abstract description 23
- 108090001008 Avidin Proteins 0.000 claims abstract description 22
- -1 acridinium compound Chemical class 0.000 claims abstract description 18
- 239000000427 antigen Substances 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims abstract description 12
- 239000007791 liquid phase Substances 0.000 claims abstract description 9
- 238000002372 labelling Methods 0.000 claims abstract description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 22
- 102000018358 immunoglobulin Human genes 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 238000003018 immunoassay Methods 0.000 claims description 19
- 239000013566 allergen Substances 0.000 claims description 14
- 229940072221 immunoglobulins Drugs 0.000 claims description 12
- 230000000977 initiatory effect Effects 0.000 claims description 9
- 238000007885 magnetic separation Methods 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 6
- YOCQHVKSRBHPIS-UHFFFAOYSA-N CC1=CC=C2N=C(C=CC=C3)C3=CC2=C1C.ON(C(CC1)=O)C1=O Chemical compound CC1=CC=C2N=C(C=CC=C3)C3=CC2=C1C.ON(C(CC1)=O)C1=O YOCQHVKSRBHPIS-UHFFFAOYSA-N 0.000 claims description 4
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 claims description 4
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 claims description 3
- 238000004020 luminiscence type Methods 0.000 claims description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 3
- 108010039862 Biotene Proteins 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 41
- 210000002966 serum Anatomy 0.000 description 20
- 241000746983 Phleum pratense Species 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 238000003556 assay Methods 0.000 description 11
- 239000013610 patient sample Substances 0.000 description 11
- 238000011002 quantification Methods 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000013060 biological fluid Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000008351 acetate buffer Substances 0.000 description 4
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229940043517 specific immunoglobulins Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 241000435275 Candidatus Cardinium Species 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000004138 Stearyl citrate Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940085298 biotin 10 mg Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000010842 industrial wastewater Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000004476 near response Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK921379A DK137992D0 (da) | 1992-11-13 | 1992-11-13 | Fremgangsmaade til paavisning af et immunologisk aktivt stof i en proeve under anvendelse af et maerkningsstof |
| PCT/DK1993/000373 WO1994011734A1 (en) | 1992-11-13 | 1993-11-15 | Two-site immunoassay for an antibody with chemiluminescent label and biotin bound ligand |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO951875L NO951875L (no) | 1995-05-11 |
| NO951875D0 NO951875D0 (no) | 1995-05-11 |
| NO320170B1 true NO320170B1 (no) | 2005-11-07 |
Family
ID=8104222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19951875A NO320170B1 (no) | 1992-11-13 | 1995-05-11 | Fremgangsmate for a male konsentrasjonen og/eller det relative innholdet av et spesifikt antistoff i en prove og anvendelser derav. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0669000B1 (de) |
| JP (1) | JP3194585B2 (de) |
| KR (1) | KR100306433B1 (de) |
| AT (1) | ATE152834T1 (de) |
| AU (1) | AU682478B2 (de) |
| CA (1) | CA2149340C (de) |
| DE (1) | DE69310537T2 (de) |
| DK (2) | DK137992D0 (de) |
| ES (1) | ES2103559T3 (de) |
| FI (1) | FI111194B (de) |
| HU (1) | HU216876B (de) |
| NO (1) | NO320170B1 (de) |
| PL (2) | PL173033B1 (de) |
| RU (1) | RU2132070C1 (de) |
| WO (1) | WO1994011734A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2289334B (en) * | 1994-05-10 | 1998-08-26 | Molecular Light Technology Lim | Enzyme linked chemiluminescent assay |
| GB9526599D0 (en) | 1995-12-28 | 1996-02-28 | Sandoz Ltd | Elisa test system |
| US6288803B1 (en) | 1997-10-27 | 2001-09-11 | Denso Corporation | Hologram display |
| US6379909B1 (en) | 1998-06-24 | 2002-04-30 | Alk-Abello A/S | Method of detecting an antibody in a liquid sample |
| WO1999067642A2 (en) * | 1998-06-24 | 1999-12-29 | Alk-Abelló A/S | Method of detecting an antibody in a liquid sample |
| US7759133B2 (en) | 1998-12-22 | 2010-07-20 | Alk-Abello A/S | Method of detecting and/or quantifying a specific IgE antibody in a liquid sample |
| US7732157B1 (en) | 1999-09-30 | 2010-06-08 | Tumor Biology Investment Group | Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods |
| GB0029154D0 (en) | 2000-11-30 | 2001-01-17 | Lee Helen | Signal enhancement with multiple labelled-antibodies |
| US7867715B2 (en) | 2003-08-05 | 2011-01-11 | Alk-Abello A/S | Method of evaluating the immunological activity of a vaccine |
| DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
| KR102164513B1 (ko) * | 2018-05-14 | 2020-10-12 | (주)상지엔지니어링건축사사무소 | 무동력 친환경 환풍구 구조 |
| WO2022256568A1 (en) * | 2021-06-02 | 2022-12-08 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for localization of growth factors |
-
1992
- 1992-11-13 DK DK921379A patent/DK137992D0/da not_active Application Discontinuation
-
1993
- 1993-11-15 DE DE69310537T patent/DE69310537T2/de not_active Expired - Lifetime
- 1993-11-15 HU HU9501413A patent/HU216876B/hu not_active IP Right Cessation
- 1993-11-15 PL PL93309004A patent/PL173033B1/pl not_active IP Right Cessation
- 1993-11-15 ES ES94900067T patent/ES2103559T3/es not_active Expired - Lifetime
- 1993-11-15 JP JP51161794A patent/JP3194585B2/ja not_active Expired - Fee Related
- 1993-11-15 RU RU95112753A patent/RU2132070C1/ru not_active IP Right Cessation
- 1993-11-15 KR KR1019950701925A patent/KR100306433B1/ko not_active IP Right Cessation
- 1993-11-15 CA CA002149340A patent/CA2149340C/en not_active Expired - Fee Related
- 1993-11-15 DK DK94900067.3T patent/DK0669000T3/da active
- 1993-11-15 AT AT94900067T patent/ATE152834T1/de not_active IP Right Cessation
- 1993-11-15 AU AU54625/94A patent/AU682478B2/en not_active Ceased
- 1993-11-15 PL PL93315871A patent/PL173049B1/pl not_active IP Right Cessation
- 1993-11-15 EP EP94900067A patent/EP0669000B1/de not_active Expired - Lifetime
- 1993-11-15 WO PCT/DK1993/000373 patent/WO1994011734A1/en active IP Right Grant
-
1995
- 1995-05-11 NO NO19951875A patent/NO320170B1/no not_active IP Right Cessation
- 1995-05-12 FI FI952330A patent/FI111194B/fi active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2103559T3 (es) | 1997-09-16 |
| FI111194B (fi) | 2003-06-13 |
| DE69310537T2 (de) | 1997-11-27 |
| FI952330A0 (fi) | 1995-05-12 |
| DE69310537D1 (de) | 1997-06-12 |
| PL309004A1 (en) | 1995-09-18 |
| DK0669000T3 (da) | 1997-12-08 |
| RU2132070C1 (ru) | 1999-06-20 |
| HUT71780A (en) | 1996-02-28 |
| DK137992D0 (da) | 1992-11-13 |
| PL173049B1 (pl) | 1998-01-30 |
| ATE152834T1 (de) | 1997-05-15 |
| EP0669000A1 (de) | 1995-08-30 |
| JPH08503071A (ja) | 1996-04-02 |
| AU682478B2 (en) | 1997-10-09 |
| HU216876B (hu) | 1999-09-28 |
| CA2149340A1 (en) | 1994-05-26 |
| AU5462594A (en) | 1994-06-08 |
| WO1994011734A1 (en) | 1994-05-26 |
| CA2149340C (en) | 2005-01-11 |
| KR950704686A (ko) | 1995-11-20 |
| JP3194585B2 (ja) | 2001-07-30 |
| KR100306433B1 (ko) | 2001-11-30 |
| PL173033B1 (pl) | 1998-01-30 |
| EP0669000B1 (de) | 1997-05-07 |
| FI952330A (fi) | 1995-05-12 |
| NO951875L (no) | 1995-05-11 |
| NO951875D0 (no) | 1995-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10732111B2 (en) | Automated immunoanalyzer system for performing diagnostic assays for allergies and autoimmune diseases | |
| US6087188A (en) | Two-site immunoassay for an antibody with chemiluminescent label and biotin bound ligand | |
| AU2018374469B2 (en) | Target interference suppressed anti-drug antibody assay | |
| US8956823B2 (en) | Anti-antibody reagent | |
| EP0722087B1 (de) | Mess-system unter verwendung von vollblut | |
| CN108508001A (zh) | 化学发光检测试剂盒 | |
| NO320170B1 (no) | Fremgangsmate for a male konsentrasjonen og/eller det relative innholdet av et spesifikt antistoff i en prove og anvendelser derav. | |
| KR20010025027A (ko) | 면역측정시약 및 면역측정법 | |
| WO2010013525A1 (ja) | 複合体の測定方法およびそれに用いるキット | |
| CN112129933B (zh) | 一种免疫分析系统中抗生物素干扰的试剂、试剂盒及方法 | |
| US20100297778A1 (en) | Conjugate Having Cleavable Linking Agent | |
| JP3228791B2 (ja) | 検体中の抗原又は抗体の測定法 | |
| JPH08220095A (ja) | 沈殿可能な固相を用いる不均一系イムノアッセイ | |
| JPWO2004061452A1 (ja) | 抗体の測定方法 | |
| CA2137238A1 (en) | Immunoassay method | |
| WO2020047735A1 (zh) | 一种基于磁微粒的时间分辨荧光免疫检测方法 | |
| CA2172840C (en) | Measuring method using whole blood sample | |
| CN111868526A (zh) | 减少免疫测定中的干扰 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |